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Abstract
The application of paired-end next generation sequencing approaches has made it possible to systematically
characterize rearrangements of the cancer genome to base-pair level. Utilizing this approach, we report the first
detailed analysis of ovarian cancer rearrangements, comparing high-grade serous and clear cell cancers, and
these histotypes with other solid cancers. Somatic rearrangements were systematically characterized in eight
high-grade serous and five clear cell ovarian cancer genomes and we report here the identification of > 600
somatic rearrangements. Recurrent rearrangements of the transcriptional regulator gene, TSHZ3, were found
in three of eight serous cases. Comparison to breast, pancreatic and prostate cancer genomes revealed that a
subset of ovarian cancers share a marked tandem duplication phenotype with triple-negative breast cancers. The
tandem duplication phenotype was not linked to BRCA1/2 mutation, suggesting that other common mechanisms
or carcinogenic exposures are operative. High-grade serous cancers arising in women with germline BRCA1 or
BRCA2 mutation showed a high frequency of small chromosomal deletions. These findings indicate that BRCA1/2
germline mutation may contribute to widespread structural change and that other undefined mechanism(s), which
are potentially shared with triple-negative breast cancer, promote tandem chromosomal duplications that sculpt
the ovarian cancer genome.
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Introduction
Somatically acquired structural genomic rearrange-
ments are common in most solid cancers and are espe-
cially so in ovarian cancer [1]. Ovarian cancer is a
collective term for a number of distinctly different
histotypes and tumours of varying degrees of malig-
nancy [2]. The most common epithelial ovarian can-
cer histotypes include serous, clear cell, mucinous and
endometrioid. Amongst these, high-grade serous can-
cers (HGSCs) are the most common, accounting for
approximately 70% of all cases of invasive epithelial
ovarian cancer and the majority of deaths.
Increasingly comprehensive genomic analyses of
HGSCs and clear cell cancers are providing insights
into pathways of transformation and the molecular
determinants of response to therapy. Our previous
gene expression profiling of HGSCs identified four
molecular subtypes [3], which are associated with
different clinical outcomes [3,4]. A signalling pathway
involving MYCN, LIN28B and LET7 is associated with
one of the four subtypes [4], suggesting that specific
pathway activation may drive the development and
Copyright  2012 Pathological Society of Great Britain and Ireland. J Pathol 2012; 227: 446–455
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
Structural rearrangements in ovarian tumours 447
behaviour of one or more HGSCs molecular subtypes.
DNA copy number analyses have shown that gains and
losses are particularly frequent in HGSCs [5,6], with a
high level of genomic disorganization apparent in most
cancer samples. A recent detailed genomic analysis
of 500 HGSCs by the TCGA consortium identified
frequently amplified and deleted regions of the HGSC
genome [1]. Approximately 50% of HGSCs had defects
in the BRCA1/2 pathway, either through germline or
somatic mutation or methylation of pathway members.
Clear cell cancers are associated with endometriosis
[7], and have been recently found to harbour somatic
mutations in the ARID1A gene in approximately 50%
of tumours [8,9]. The patterns of gene expression and
copy number change seen in clear cell ovarian cancer
are distinct from HGSCs, and frequently involve ampli-
fication and over expression of cytokines including
IL6, receptor tyrosine kinases and other downstream
signalling components [10,11]. The gene expression
profiles of ovarian clear cell cancers are similar to
renal and uterine clear cell tumours [12]. Favourable
responses have been observed in a small number of
ovarian clear cell patients to sunitinib [10], a drug with
considerable activity in renal clear cell cancer.
Next-generation DNA sequence analysis is providing
an unprecedented level of information about the can-
cer genome, identifying new mutations [9,13,14], the
impact of mutagens [15,16] and novel processes that
sculpt the cancer genome [17]. Here we used paired-
end DNA sequencing to seek novel gene fusions and
characterize structural changes in ovarian cancer sam-
ples, comparing and contrasting HGSCs and clear cell
genomes.
Materials and methods
Patient samples and ethics
Tumour samples and clinical data were obtained from
women enrolled in the Australian Ovarian Cancer
Study (www.aocstudy.org). All participants provided
written informed consent and Human Research Ethics
Committee approval was obtained at the Peter Mac-
Callum Cancer Centre (Queensland Institute of Medi-
cal Research, University of Melbourne, Australia) and
all participating hospitals for the study. Further clini-
cal data, information on biospecimens and microarray
analysis are described in the Supplementary methods
(see Supporting information).
Next-generation sequencing
Next-generation sequencing and structural variant anal-
ysis was carried out as described previously [18].
Briefly, 37 bp paired-end reads generated on the
Illumina GA2 were aligned to the human reference
genome (hg19) using BWA. Rearrangement break-
points were called when two or more discordantly
mapped read pairs supported the same underlying
event. Breakpoints were classified according to the
relative orientations and insert sizes of the read pairs
into those suggesting deletion, translocation, inversion
or tandem duplication (insertion). Candidate break-
points were confirmed as somatic by PCR on both
tumour and matched normal DNA and mapped to base
pair resolution by capillary sequencing. Breakpoints
were classified according to the relative orientations
and insert sizes of the read pairs into those suggesting
deletion, translocation, inversion or tandem duplica-
tion (insertion). Rearrangements were further classified
based on integration with copy number data to include
amplicon junctions, fold-back inversions and genomic
shards [19].
Validation of gene rearrangements
cDNA from total RNA for sequenced samples and
validation samples was synthesized using M-MLV
reverse transcriptase (Promega), as described previ-
ously [20]. Endpoint RT–PCR was performed accord-
ing to standard protocols using Thermo-Start DNA
polymerase (ThermoScientific). Products were resolved
by agarose gel electrophoresis and samples with visi-
ble products (for CCNY/CREM and ATP9B rearrange-
ments only) were subjected to a second independent
PCR reaction with alternate primer sets. No products
were confirmed by a second PCR reaction except for
control samples, where rearrangements were initially
identified. Gene expression of TSHZ3 was measured
by quantitative reverse-transcription PCR (qRT–PCR)
normalized to ACTB and HPRT1 control genes and
median CT (threshold cycle) values obtained across
eight serous samples, using a SYBR Green qPCR assay
on the 7900HT Fast Real-Time PCR system (Applied
Biosystems, Foster City, CA, USA). RNA was treated
with DNase I (Promega) prior to cDNA synthesis to
eliminate background amplification of genomic DNA.
Primer details are given in Table S4 (see Supporting
information).
Germline and somatic analysis of BRCA pathway
dysfunction
Complete germline sequencing of BRCA1 and BRCA2
and multiplex ligation-dependent probe amplification
(MLPA) for detection of large chromosomal aberra-
tions were undertaken in the National Association
of Testing Authorities (NATA) accredited Molecular
Pathology Laboratory at the Peter MacCallum Can-
cer Centre. Detailed methods are provided elsewhere
(Alsop et al, in press). Somatic mutations in tumour
samples were screened by high-resolution melt (HRM)
analysis of all coding exons of BRCA1 and BRCA2, as
described by others [21]. Gene promoter methylation
of tumour DNA was assessed for BRCA1, FANCF and
PALB2 using methylation-sensitive HRM, as described
previously [22]. Reported percentage of methylated
allele present in tumour DNA was estimated by com-
parison to a panel of control samples. No promoter
methylation of FANCF or PALB2 was identified in
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the 13 samples screened, and only one sample showed
promoter methylation of BRCA1 (see Supporting infor-
mation, Table S1).
Results
To identify DNA rearrangements in ovarian cancer
genomes, we carried out paired end sequencing of
tumour DNA from 13 ovarian tumour samples (eight
HGSCs and five clear cell; see Supporting informa-
tion, Table S1). A total of 1.1 × 109 37 bp read pairs
generated 7 × 1010 base pairs that could be assigned
uniquely to the reference genome equating to 4.3–16.5-
fold physical coverage per sample. Putative structural
rearrangements were identified from incorrectly map-
ping read pairs [18,23] and 634 confirmed somatically
acquired DNA rearrangements were identified across
13 ovarian cancers (range 13–150/sample), with base
pair sequence level resolution of 598 individual break-
points (94%; see Supporting information, Table S2).
Each genome displayed a different spectrum of unique
somatically acquired rearrangements (Figure 1), with
varying proportions of rearrangements in each class
(Table 1).
By classifying tumours according to the dominant
class of rearrangement, three distinct mutation profiles
were observed in HGSCs. In four of the HGSCs, half
or more of the chromosomal rearrangements involved
tandem duplications (median 410 kb), including one
case with 81 tandem duplication events detected
(PD3722a). For three HGSCs, deletions were the dom-
inant rearrangement class, with the remaining serous
cancer sample having a genome dominated by junc-
tions within amplicons (Table 1). The three cases
showing a high frequency of deletions had either
a germline BRCA1 or BRCA2 mutation (PD3724a,
PD3726a and PD3731a) and the deletions in these
cases were small (median 3.2 kb) when compared to
deletions in cases without germline BRCA1 /2 muta-
tions (median 288 kb). Over-representation of deletions
in BRCA1/2 mutant compared to wild-type cases as a
proportion of all rearrangements was statistically sig-
nificant (p < 3.91 × 10−11 by a Poisson regression
test). Two HGSCs cases with somatic alteration of
BRCA1, either through point mutation or promoter
hypermethylation (PD3722a and PD3725a, respec-
tively), did not show the deletion/translocation pheno-
type. Fewer rearrangements were observed in ovarian
clear cell cancers compared with HGSCs (Table 1),
consistent with our previous copy number analysis
[10]. The types of rearrangement present within each
genome were more evenly distributed between the
classes in the clear cell histotype. Tandem duplications
were the dominant class in all five clear cell cases, but
relatively high proportions of translocations, deletions
and inversions were also seen (Table 1). Statistical
analyses utilizing a generalized linear model (GLM)
PD3723a
PD3730aPD3728a
Serous
PD3722a
Clear Cell
PD3753a PD3756a PD3759a PD3760a PD3761a
BRCA1 somatic
PD3724a
BRCA2 germline
PD3731a
BRCA1 germline
PD3725a
BRCA1 methylated
PD3726a
BRCA2 germline
BRCA1 polymorphism
Figure 1. Genomic rearrangements of 13 ovarian cancer genomes. The chromosomes of the reference genome are drawn around the
circumference of each circos plot [42]. Rearrangements are represented by lines linking somatically acquired breakpoints: orange, fold
back inversions; light blue, one or both end map to an amplicon; purple, translocations; green, inversions; red, tandem duplications; dark
blue, deletions. BRCA1/2 mutation status or mechanism of inactivation indicated.
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Table 1. Breakpoint frequencies in 13 ovarian cancer cases illustrating correlations with BRCA1/2 status and histotype
Tandem
BRCA Total Translocations Deletions duplications Amplicons Inversions Fold- Shards
Sample Histotype status breakpoints (%) (%) (%) (%) (%) back (%)
PD3722a Serous Somatic
(BRCA1)
114 4 7 71 7 8 2 2
PD3723a Serous Wt 37 8 3 68 3 11 8 0
PD3724a Serous Germline
(BRCA2)
150 24 51 13 3 6 1 3
PD3725a Serous Methylated
(BRCA1)
19 11 16 68 0 5 0 0
PD3726a Serous Germline
(BRCA2)
60 22 42 17 0 18 0 2
PD3728a Serous Wt 75 9 19 16 36 5 11 4
PD3730a Serous Wt 21 10 29 48 10 0 5 0
PD3731a Serous Germline
(BRCA1)
30 23 27 20 17 7 3 3
PD3753a Clear cell Wt 31 32 3 58 0 6 0 0
PD3756a Clear cell Wt 39 23 10 62 3 3 0 0
PD3759a Clear cell Wt 30 27 17 30 0 20 0 7
PD3760a Clear cell Wt 15 7 7 73 0 7 0 7
PD3761a Clear cell Polymorphism
of likely low
clinical
significance
13 8 23 38 0 23 8 0
Categories with the highest proportion of breaks for each tumour are in bold italics.
approach indicated that the occurrence of deletions
(p = 0.0053) and amplicons (p = 0.010) was signif-
icantly different between clear cell and HGSCs cases.
Further, the overall p value for the probability that the
distributions differ (from the log likelihood, when com-
pared against the null model of no interaction between
cancer type and rearrangement class distribution) was
3.13 × 10−6.
We have previously observed high proportions of
tandem duplications in a subset of breast cancer
genomes [23]. Given the apparent similarity in pat-
tern and distribution of this class of rearrangement, we
undertook a comparative analysis of ovarian and other
solid cancers for which data was available. Although
HGSCs and clear cell cancers are considered to have
different aetiologies and patterns of somatic mutation,
we considered them as a single group for the pur-
poses of the analysis, as tandem duplications were
found in both histotypes. We compared 634 ovarian
cancer rearrangements identified in this study, with
994 rearrangements identified in primary breast can-
cers [23], 352 rearrangements in pancreatic cancers
[19] and 464 rearrangements recently reported in an
analysis of seven prostate cancer genomes [24]. Com-
paring the proportions of each class of rearrangement in
each cancer type revealed significant differences (χ2p
value for effects of interaction between cancer type
and rearrangement type = 1.88 × 10−68). There were
significantly more tandem duplications in breast and
ovarian cancers compared to pancreatic and prostate
cancers (p = 1.6 × 10−12). Amplified fold back inver-
sions were much more common in pancreatic than
breast or ovarian cancers (p = 4.94 × 10−04).
In total, 371 (59%) of the somatic rearrangement
breakpoints identified in this study fell in or within
10 kb of gene ‘footprints’ (ie within Ensembl gene
coordinate boundaries), with 16 gene footprints dis-
rupted in more than one sample (see Supporting infor-
mation, Table S3). While these mostly occurred in
genes with large genomic footprints, suggesting that a
proportion are likely passenger events, several warrant
further consideration. TSHZ3, a homeobox transcrip-
tion factor that has been implicated in ureter formation
[25] and development of respiratory neurons [26], was
the most commonly disrupted gene, occurring in 3/8
HGSC samples. The breakpoints (caused by transloca-
tion, inversion or tandem duplication) all lie in the only
intron and map within 29 kb of each other (Figure 2A).
The gene is approximately 74 kb in length and we have
not found it deleted in other cancer types previously
(unpublished data).
Rearrangement of TSHZ3 was further explored by
two-colour FISH analysis of 90 HGSCs samples on
tissue microarrays (TMA), which included three cases
(PD3722a, PD3724a, PD2728a) identified in the rear-
rangement screen. In total, 11/90 HGSC cases were
found to have rearrangements involving the TSHZ3
locus. The small tandem duplication in PD3722a was
not detectable on TMA FISH, whilst the transloca-
tion in PD3724a was readily confirmed. The inver-
sion in PD3728a was not discernable on FISH; how-
ever, the locus was amplified. In the remaining cases,
there were two main patterns of rearrangement, split
roughly equally between amplification and rearrange-
ment breaks in the gene, including two cases with
apparently balanced breaks, confirming TSHZ3 as
recurrently rearranged (Figure 2B).
Assessing the importance of TSHZ3 in ovarian can-
cer is confounded by its proximity to CCNE1, mapping
1.45 Mb telomeric on 19q12 (Figure 2C). CCNE1 is
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Figure 2. (A) Wild-type TSHZ3 locus (top) and schematics of the three rearrangements identified by next-generation sequencing. (B) Tissue
microarray images of four cases with varying TSHZ3 rearrangements: (1) loss of the 5′ end of TSHZ3 with example of locus without
rearrangement indicated by a white arrow; (ii) balanced break; (iii) amplification; and (iv) breakage with amplification of the 3′ end of
TSHZ3. Green, BAC probes RP11-280H11 and RP11-241C16 (5′ TSHZ3); red, RP11-161K19 and RP11-164O11 (3′ TSHZ3). (C) Affymetrix
SNP 6.0 copy number data for tumour sample PD7231a, showing multiple focal amplifications incorporating CCNE1 and TSHZ3. (D) Scatter
plot of TSHZ3 expression by gene copy number status, where amplification is > three copies. (E) Scatter plot showing TSHZ3 gene
expression by qRT–PCR (left) and gene expression microarray (right) in rearranged tumours (open circles) compared to samples without
gene rearrangement (closed circles).
known to be amplified and operative as a cancer gene
in serous ovarian cancer [27], and the breakpoints in
TSHZ3 could be collateral to amplification involving
CCNE1. To further evaluate this, those TMA cases
with TSHZ3 breakpoints and available DNA (n = 10)
were evaluated using Affymetrix SNP 6.0 gene arrays
for evidence of independence from CCNE1 ampli-
fication. Five of 10 cases had high-level amplifica-
tion of CCNE1 with associated gain and breaks in
TSHZ3, a frequency substantially above the 15–20%
seen in unselected cases [20]. Sample PD7231a shows
a complex pattern of copy number change, includ-
ing multiple, focal, high-level amplifications incorpo-
rating both CCNE1 and TSHZ3 (Figure 2C). In this
case, TSHZ3 and CCNE1 are on separate segments,
although they are presumably co-amplified. Of the five
cases without CCNE1 amplification, four had evidence
for low-level copy-number gain (copy numbers 3 or
4) of both TSHZ3 and CCNE1, with TSHZ3 break-
points detectable on SNP array in two of the cases;
PD7229a and PD7730a both had balanced rearrange-
ments on FISH and were not detectable on SNP array,
as expected. In the remaining case, PD3722a, there was
no copy number gain for TSHZ3 other than the small
tandem duplication of the locus, whereas CCNE1 had
a single copy gain. These data suggest that TSHZ3
rearrangement can occur at least in some instances
independently of CCNE1 amplification. Additionally,
Affymetrix SNP 6.0 data obtained from the TCGA
ovarian cancer study (see Methods) was also evalu-
ated for independent breakpoints affecting TSHZ3 in
the absence of CCNE1 amplification. This analysis
revealed five cases with evidence for TSHZ3 break-
points apparently unrelated to CCNE1 gain or ampli-
fication.
Quantitative RT–PCR analysis showed TSHZ3 expres-
sion was not associated with gene amplification
(Figure 2D); however, there was evidence of reduced
expression of TSHZ3 in rearranged cases compared
with HGSCs without disruption of the locus (Figure 2E).
We also compared gene expression by microarray,
using probe sets detecting transcripts across exon 1
and 2 boundaries (223392_s_at) and within exon 2
only (223393_s_at). No differences between probe sets
were detected in rearranged versus wild-type samples,
suggesting that there is no aberrant transcription of
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short transcripts (Figure 2E). To further identify poten-
tial fusion transcripts we employed 5′ RACE across all
eight sequenced samples. We were, however, only able
to detect wild-type products (data not shown). If novel
transcripts were generated in the rearranged samples, it
is possible that low expression may have limited their
detection.
These findings suggest that if TSHZ3 is contributing
to ovarian cancer, it may be through down-regulation
or loss of function. However, arguing against this
is the lack of truncating mutations reported in the
recently released data from whole-exome sequencing
of more than 250 serous ovarian cancers, where only
two missense and two silent somatic mutations were
identified [1].
We examined TSHZ3 gene expression further in two
large independent datasets of HGSCs (see Supporting
information, Figure S1). Although rearrangement of
TSHZ3 is associated with reduced gene expression, we
found that a high level of TSHZ3 was associated with
shorter progression-free survival only in the AOCS
dataset (p < 0.04) [3]. In both AOCS and TCGA [1]
cohorts, high TSHZ3 expression was associated with
the C1 molecular subtype, which is characterized by
intense tumour stromal and epithelial–mesenchymal
transition gene expression signatures and poor clinical
outcome.
Non-identical tandem duplications of approximately
1 and 0.5 Mb were identified in 2/8 HGSCs samples
that disrupted the gene encoding Rho GTPase activat-
ing protein 6 (ARHGAP6 ) on the X chromosome (see
Supporting information, Table S3). These two cases
were also rearranged for TSHZ3. ARHGAP6 functions
as a GAP for RhoA GTPase, which has been implicated
in cell motility, and angiogenesis and has been reported
to be up-regulated in multiple cancers, including serous
ovarian carcinomas [28]. Normally, ARHGAP6 would
serve to limit the activity of RhoA by activating the
intrinsic GTPase activity resulting in conversion to the
inactive GDP-bound form of the enzyme [29]. The
locus encodes multiple splice forms, but no signif-
icant expression differences were discernable in the
rearranged versus non-rearranged cases.
Amongst the other genes broken, ARID1A, a member
of the SWI/SNF chromatin remodelling complex, was
found to be presumptively inactivated by a ∼130 kb
inversion on chromosome 1 in the clear cell case,
PD3753a. Frequent inactivating point mutations and a
single rearrangement were recently reported in clear
cell ovarian cancer [8,9], consistent with the inactivat-
ing rearrangement identified here. Indeed, four of the
five cases reported here were also included in Wiegand
et al [9], with one case, PD3761a, having frameshift
mutation in ARID1A. Also, ARID1A has been previ-
ously implicated in other human cancers [30,31] and
recently found to be mutated recurrently in clear cell
renal cell carcinoma [32]. Additionally, breakpoints in
PPP2R2B, a component of the regulatory subunit B
of serine/threonine phosphatase 2 (PP2A) involved in
cell growth and division, were found in two samples
(one serous and one clear cell tumour). Mutations in
the PP2A regulatory subunit A component, PPP2R1A,
have previously been shown in ovarian clear cell can-
cers [8].
Although all 13 HGSCs and clear cell cases had rear-
rangements, no recurrent gene fusions were detected
amongst the discovery set of samples. Nine single
instances of in-frame fusion genes and five in-frame
internally rearranged genes were identified (Table 2),
all occurring in HGSCs. To investigate whether any of
these potential gene fusions and internally rearranged
genes were transcribed, PCR assays were designed
to the exons surrounding the genomic breakpoints
and RNA from the relevant cases was assayed by
reverse transcription (RT)–PCR. Products were suc-
cessfully amplified for 7/9 gene fusions but none of
the internally rearranged genes, indicating that a sub-
stantial proportion of in-frame fusions were expressed.
RT–PCR product sequence was verified by conven-
tional sequencing.
In order to detect recurrence of novel rearranged
transcripts in ovarian cancer, we screened cDNA from
an independent validation set of 109 HGSCs for the
same exon joining events for six of the in-frame
fusion genes found in HGSCs cases (CCNY /CREM,
NDUFA11 /STX17, AGGF1 /SCAMP1, MAP3K1 /SIRPA,
C2orf67 /MARCH4, C11orf41 /DNAJC24 ) and one of
the in-frame internally rearranged transcripts (ATP9B ).
We were unable to detect expression of any of the
fusion transcripts in the validation cohort. We next
looked for co-expression of CCNY/CREM in our
previous analysis of ovarian tumours [3]. We rea-
soned that oncogenic fusion transcripts would likely
show gene over-expression and preselection of cases
may increase the chance of detecting recurrent low-
frequency fusions. We identified 25 samples from
215 HGSCs (independent of the 109-sample valida-
tion set) that showed high expression of both CREM
and CCNY (expression above median +0.5× median
absolute deviation [MAD]), representing a statisti-
cally significantly higher proportion than would be
expected by chance (p < 0.05). From these, RNA was
available for 15 samples and analysed for expres-
sion of the CCNY/CREM fusion. No fusion prod-
ucts were detected in the selected samples, suggest-
ing that if co-expression was the result of rearrange-
ment/fusion, breakpoints varied from the originally
defined boundaries.
Discussion
The landscape of rearrangements in HGSCs and clear
cell ovarian cancers is characterized by a substan-
tial proportion of cases, showing a predominance of
tandem duplications, overlapping a phenotype previ-
ously shown in breast cancer [23]. In addition, there is
evidence for a deletion/translocation phenotype poten-
tially linked to germline BRCA1 /2 mutations, with a
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Table 2. In-frame gene fusions and internal gene rearrangements
5′ Exons in 3′ Exons in
Gene predicted Gene predicted
5′ Accession fusion Accession fusion Class of
Sample Gene No. gene 3′ Gene No. gene Expressed? rearrangement
PD3722a HGS∗ NM_004712.3 1–8 SLC16A5∗ NM_004695.2 6–7 Yes Tandem duplication
PD3722a CCNY NM_145012.4 1–11 CREM NM_181571.1 4–14b Yes Other intrachromosomal
PD3723a C2orf67 NM_152519.2 1–3 MARCH4 NM_020814.2 3–4 Yes Other intrachromosomal
PD3723a MRPL43 NM_176792.1 1–5 SH3PXD2A NM_014631.2 5–14 No Tandem duplication
PD3723a C11orf41 NM_012194.1 1–18 DNAJC24 NM_181706.4 4–5 Yes Other intrachromosomal
PD3724a AGGF1 NM_018046.3 1 SCAMP1 NM_004866.4 3–9 Yes Deletion
PD3726a NDUFA11 NM_175614.2 1–2 STX17 NM_017919.2 5–8 Yes Translocation
PD3731a MAP3K1 NM_005921.1 1–13 SIRPA NM_001040022.1 9–10 Yes Translocation
PD3760a SV2B NM_014848.3 1–8 CRTC3 NM_022769.3 11–15 No Shard (TD)
PD3722a PHACTR1 NM_030948.1 Duplication of
exons 3 & 4
No Tandem duplication
PD3722a SGCZ NM_139167.2 Duplication of
exons 2 & 3
No Tandem duplication
PD3726a CLSTN2 NM_022131.2 Deletion of
exon 2
No Other intrachromosomal
PD3728a ATP9B NM_198531.3 Duplication of
exons 12–15
ND Tandem duplication
PD3760a THSD4 NM_024817.2 Duplication of
exons 6 & 7
No Tandem duplication
∗Alternative splicing of the fusion transcript yields both in-frame and out-of-frame products. ND = not determined.
high prevalence of small deletions being particularly
marked in BRCA2 null tumours. Somatic missense
mutation and hypermethylation of BRCA1 was not,
however, associated with the same mutation phenotype.
Therefore, somatic events are unlikely to be func-
tionally equivalent to germline truncating mutations
if abrogation of BRCA1/2 function is directly linked
to the phenotype. Overall comparison between four
different tumour types suggests that multiple differ-
ent mechanisms are operative in the reconstruction of
cancer genomes, likely involving as-yet unidentified
exposures and/or genome maintenance defects.
The observed high frequency of tandem duplications
in the ovarian cancer samples, especially HGSCs cases,
adds to previous data suggesting molecular similari-
ties between triple-negative and HGSCs [33,34]. Of
note, the tandem duplication phenotype was present
in both histological subtypes of ovarian cancer. This
is of interest, as these subtypes show marked differ-
ences in cancer gene mutations found [35], expres-
sion clustering [10] and response to therapy. Given
the apparently different histogenesis [36], our findings
suggest convergent acquisition of the tandem dupli-
cation phenotype during oncogenesis. Further, tan-
dem duplication was not associated with germline
BRCA1 or BRCA2, suggesting that the phenotype is
attributable to a yet to be identified common patho-
genetic mechanism.
A recent study by Ng et al reported on the pres-
ence of a tandem duplicator phenotype in HGSCs
[37]. Genome paired-end sequencing of PEO1/PEO4
cell lines derived from a BRCA2 mutation carrier
showed interchromosomal breakpoints and small dele-
tions consistent with homologous recombination (HR)
deficiency. In contrast, the PEO14/PEO23, BRCA
wild-type cell lines had intact HR and a tandem dupli-
cator phenotype. Using SNP copy number data, a
‘tandem duplicator-like’ (TD-like) pattern was inferred
and used to estimate the phenotype frequency in the
TCGA dataset. TD-like copy number aberrations were
reported to occur in 12.8% of HGSCs and, consistent
with our findings, these were mutually exclusive to
BRCA1/2 carrier mutations.
We found no evidence of recurrent fusion genes in
our study. While less common than in haematologi-
cal malignancies and sarcomas, recurrent gene fusions
have been identified in other solid tumours, such
as TMPRSS2–ERG in prostate [38] and EML4–ALK
in non-small cell lung cancers [39]. Recently, Salz-
man et al reported on the identification of the novel
ESRRA–C11orf20 gene fusion in serous ovarian can-
cer, using an ultra-high-throughput RNA sequencing
approach [40]. Recurrence was reported in approxi-
mately 15% of cases (n = 67); however, we saw no
evidence of this rearrangement in our screen. Identifi-
cation of ESRAA–C11orf20 fusions may have been
limited by a low frequency of recurrence and the
small number of serous tumours analysed in our
study.
TSHZ3 was identified as a target of recurrent break-
age in ovarian cancer. Gene expression analysis sug-
gests that if TSHZ3 is contributing to pathogene-
sis, it may be through loss of function or simply
down-regulation. Inactivation of TSHZ3 in vivo shows
clear gene dosage effects, leading to haploinsuffi-
ciency, neonatal lethality and reduced heterozygote pup
size compared to wild-type siblings [26]. Additionally,
TSHZ3 has recently been shown to be among the most
down-regulated genes in breast and prostate cancer,
suggesting likely relevance in various tumour types
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[41]. Additional work is warranted to clarify mecha-
nisms of deregulation and the role of TSHZ3 in ovarian
cancer.
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